InvestSMART

Imagion Biosystems Limited (ASX:IBX)

ALERT: Price-sensitive ASX Announcement for IBX
Current share price for IBX : $0.012 -0.01 (-45.45%)+
Announcement
Release
23 Apr 2026 12:16PM
Price at Release
$0.022
Full Release
download
Summary
Imagion Biosystems Limited released its Quarterly Activities Report and Appendix 4C for the quarter ending 31 March 2026. The company, which focuses on early cancer detection with its MagSense® technology, announced the submission of an Investigational New Drug (IND) application to the FDA for Phase 2 clinical trials targeting HER2 positive breast cancer. The clinical-study site engagements and manufacturing activities are progressing in preparation for the trial's anticipated start in Q2 2026. The financial report indicated an operating cash outflow of AU$1.279 million, with a cash balance of AU$0.273 million as of 31 March 2026. The company has an unused finance facility of AU$11.08 million. Imagion also amended its convertible note agreement with Mercer Street Global Opportunity Fund, increasing the facility by $300,000 and extending the maturity date.
Key Points
  • IND application submitted for Phase 2 HER2 breast cancer trials.
  • Clinical-study site engagements completed in the USA.
  • Operating cash outflow of AU$1.279 million reported.
  • Cash balance of AU$0.273 million as of 31 March 2026.
  • AU$11.08 million finance facility unused.
  • Convertible note agreement with Mercer Street amended.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.